| Original language | English (US) |
|---|---|
| Pages (from-to) | 2284-2287 |
| Number of pages | 4 |
| Journal | Journal of cardiovascular electrophysiology |
| Volume | 31 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2020 |
Funding
Dr. Ravi Patel is supported by the National Institutes of Health's National Center for Advancing Translational Sciences (KL2TR001424). Dr. Rod Passman is on the advisory board for Abbott and Medtronic and receives royalties from UpToDate. Dr. Sanjiv Shah is the principal investigator of the Corvia REDUCE LAP‐HF I and II trials, and has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer‐Ingelheim, Bristol Myers Squibb, Cardiora, Cyclerion, Cytokinetics, Eisai, Ionis, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Sanofi, Shifamed, Tenax, and United Therapeutics. Disclosures:
Keywords
- atrial fibrillation
- clinical trial
- heart failure with preserved ejection fraction
- left atrium
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
